Oncology Institute Stock Beta
| TOI Stock | USD 0.17 0.02 13.33% |
Oncology Institute fundamentals help investors to digest information that contributes to Oncology Institute's financial success or failures. It also enables traders to predict the movement of Oncology Stock. The fundamental analysis module provides a way to measure Oncology Institute's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Oncology Institute stock.
Oncology | Beta |
Oncology Institute Company Beta Analysis
Oncology Institute's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Oncology Institute Beta | 0.62 |
Most of Oncology Institute's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Oncology Institute is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Oncology Beta Driver Correlations
Understanding the fundamental principles of building solid financial models for Oncology Institute is extremely important. It helps to project a fair market value of Oncology Stock properly, considering its historical fundamentals such as Beta. Since Oncology Institute's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Oncology Institute's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Oncology Institute's interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Oncology Institute has a Beta of 0.616. This is 28.37% lower than that of the Health Care Equipment & Supplies sector and significantly higher than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Oncology Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Oncology Institute's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Oncology Institute could also be used in its relative valuation, which is a method of valuing Oncology Institute by comparing valuation metrics of similar companies.Oncology Institute is currently under evaluation in beta category among its peers.
Oncology Institute Institutional Holders
Institutional Holdings refers to the ownership stake in Oncology Institute that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Oncology Institute's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Oncology Institute's value.| Shares | Freegulliver, Llc | 2024-09-30 | 188.2 K | Renaissance Technologies Corp | 2024-09-30 | 170 K | Millennium Management Llc | 2024-06-30 | 109.2 K | State Street Corp | 2024-06-30 | 101.3 K | Saba Capital Management, Lp | 2024-06-30 | 94.3 K | Citadel Advisors Llc | 2024-09-30 | 91.3 K | Fielder Capital Group Llc | 2024-09-30 | 70.2 K | Northern Trust Corp | 2024-09-30 | 64.9 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 58.7 K | Fmr Inc | 2024-09-30 | 4.7 M | Deerfield Management Co | 2024-09-30 | 3.4 M |
As returns on the market increase, Oncology Institute's returns are expected to increase less than the market. However, during the bear market, the loss of holding Oncology Institute is expected to be smaller as well.
Oncology Fundamentals
| Return On Equity | -1.26 | ||||
| Return On Asset | -0.19 | ||||
| Profit Margin | (0.20) % | ||||
| Operating Margin | (0.17) % | ||||
| Current Valuation | 88.39 M | ||||
| Shares Outstanding | 75.56 M | ||||
| Shares Owned By Insiders | 19.55 % | ||||
| Shares Owned By Institutions | 47.59 % | ||||
| Number Of Shares Shorted | 421.89 K | ||||
| Price To Earning | 190.67 X | ||||
| Price To Book | 0.83 X | ||||
| Price To Sales | 0.04 X | ||||
| Revenue | 324.24 M | ||||
| Gross Profit | 52.09 M | ||||
| EBITDA | (70.45 M) | ||||
| Net Income | (83.07 M) | ||||
| Cash And Equivalents | 64.21 M | ||||
| Cash Per Share | 0.89 X | ||||
| Total Debt | 119.67 M | ||||
| Debt To Equity | 0.15 % | ||||
| Current Ratio | 3.11 X | ||||
| Book Value Per Share | 0.77 X | ||||
| Cash Flow From Operations | (36.31 M) | ||||
| Short Ratio | 3.38 X | ||||
| Earnings Per Share | (0.77) X | ||||
| Target Price | 2.0 | ||||
| Number Of Employees | 800 | ||||
| Beta | 0.62 | ||||
| Market Capitalization | 12.85 M | ||||
| Total Asset | 209.24 M | ||||
| Retained Earnings | (146.15 M) | ||||
| Working Capital | 108.7 M | ||||
| Net Asset | 209.24 M |
About Oncology Institute Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Oncology Institute's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oncology Institute using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oncology Institute based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Oncology Institute offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Oncology Institute's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Oncology Institute Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Oncology Institute Stock:Check out Oncology Institute Piotroski F Score and Oncology Institute Altman Z Score analysis. For more detail on how to invest in Oncology Stock please use our How to Invest in Oncology Institute guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oncology Institute. If investors know Oncology will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oncology Institute listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.77) | Revenue Per Share 4.873 | Quarterly Revenue Growth 0.229 | Return On Assets (0.19) | Return On Equity (1.26) |
The market value of Oncology Institute is measured differently than its book value, which is the value of Oncology that is recorded on the company's balance sheet. Investors also form their own opinion of Oncology Institute's value that differs from its market value or its book value, called intrinsic value, which is Oncology Institute's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oncology Institute's market value can be influenced by many factors that don't directly affect Oncology Institute's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oncology Institute's value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncology Institute is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncology Institute's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.